Amlodipine Inhibits Vascular Cell Senescence and Protects Against Atherogenesis Through the Mechanism Independent of Calcium Channel Blockade
-
- Kayamori Hiromi
- Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences
-
- Shimizu Ippei
- Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences Division of Molecular Aging and Cell Biology, Niigata University Graduate School of Medical and Dental Sciences
-
- Yoshida Yohko
- Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences Division of Molecular Aging and Cell Biology, Niigata University Graduate School of Medical and Dental Sciences
-
- Hayashi Yuka
- Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences
-
- Suda Masayoshi
- Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences
-
- Ikegami Ryutaro
- Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences
-
- Katsuumi Goro
- Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences
-
- Wakasugi Takayuki
- Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences
-
- Minamino Tohru
- Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences
Search this article
Abstract
<p>Vascular cells have a finite lifespan and eventually enter irreversible growth arrest called cellular senescence. We have previously suggested that vascular cell senescence contributes to the pathogenesis of human atherosclerosis. Amlodipine is a mixture of two enantiomers, one of which (S- enantiomer) has L-type channel blocking activity, while the other (R+ enantiomer) shows ~1000-fold weaker channel blocking activity than S- enantiomer and has other unknown effects. It has been reported that amlodipine inhibits the progression of atherosclerosis in humans, but the molecular mechanism of this beneficial effect remains unknown. Apolipoprotein E-deficient mice on a high-fat diet were treated with amlodipine, its R+ enantiomer or vehicle for eight weeks. Compared with vehicle treatment, both amlodipine and the R+ enantiomer significantly reduced the number of senescent vascular cells and inhibited plaque formation to a similar extent. Expression of the pro-inflammatory molecule interleukin-1β was markedly upregulated in vehicle-treated mice, but was inhibited to a similar extent by treatment with amlodipine or the R+ enantiomer. Likewise, activation of p53 (a critical inducer of senescence) was markedly suppressed by treatment with amlodipine or the R+ enantiomer. These results suggest that amlodipine inhibits vascular cell senescence and protects against atherogenesis at least partly by a mechanism that is independent of calcium channel blockade.</p>
Journal
-
- International Heart Journal
-
International Heart Journal 59 (3), 607-613, 2018-05-31
International Heart Journal Association
